Suggested remit: To appraise the clinical and cost effectiveness of apadamtase alfa within its marketing authorisation for treating congenital thrombotic thrombocytopenic purpura.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6192
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6192:
- 21 January 2026 - 18 February 2026
- Scoping workshop:
- 13 March 2026 (14:00)
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 January 2026 | In progress. Scoping commencing |
| 04 November 2025 | Please note that following on from information received from the company, the timelines for this evaluation have been scheduled and the evaluation is now anticipated to begin in mid-April 2026. |
| 11 August 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 26 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual